ClinicalTrials.gg
CompletedNCT06164743Updated Sep 11, 2026Results posted

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

A Phase 2 interventional study of VVN461 Ophthalmic Solution 1.0% and VVN461 Ophthalmic Solution 0.5% in Inflammation, sponsored by VivaVision Biotech, Inc. Completed at 10 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by VivaVision Biotech, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.

Enrollment
245th of 956
91 · median 45
Started
2024
with 41 others
Phase 2
172 of 1,173
21 open now
Registered
1,041st of 1,173
by date

Among the 1,173 studies in Inflammation with a site in United States, this one is the 245th largest by enrollment of the 956 interventional ones that give a count, is one of 42 that started in 2024, is one of 172 in phase 2, and was the 1,041st registered.

Inflammation

3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.

Browse Inflammation studies →

Open to participants now

161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,173 studies in Inflammation with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification

Read the detailed description

This is a phase 2, multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the US assessing the safety and ocular efficacy of VVN461 for treating post-operative ocular inflammation in subjects who undergo routine unilateral CELR surgery via phacoemulsification without surgical complication. Approximately 90 subjects (30 per group) will be randomized in a 1:1:1 ratio. Subjects will administer 1 eye drop in the study eye four times a day (QID) for 14 days.

03

Conditions studied

  • Inflammation

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥21 years of age and in good general health at Visit 1 (Screening)
  • Willing and able to provide and provide relevant privacy authorization(s)
  • Willing and able to comply with study requirements and visit schedule
  • Clear ocular media (other than cataract) in the study eye
  • Planning to undergo routine unilateral cataract surgery via phacoemulsification extraction and implantation of an intraocular lens.

Exclusion criteria

Exclusion Criteria:

  • Any ocular pain at Visit 1 (Screening)
  • Recent use of or oral non-steroidal anti-inflammatory drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    VVN461 1.0%

    VVN461 Ophthalmic Solution, 1.0%

    Drug: VVN461 Ophthalmic Solution 1.0%

  • Experimental
    VVN461 0.5%

    VVN461 Ophthalmic Solution, 0.5%

    Drug: VVN461 Ophthalmic Solution 0.5%

  • Placebo comparator
    Vehicle

    VVN461 Vehicle

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Anterior Chamber Cell (ACC): Categorical Cure

    Proportion of subjects with grade of 0 using SUN Working Group Grading Scale (0 (none) to 4+ (\>50 cells in field). Note - higher values represent a WORSE outcome.

    Time frame: Day 14

Secondary outcomes

  1. Safety of VVN461

    Number of subjects with Adverse Events

    Time frame: Day 21

07

Results

Posted Jun 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneVVN461 1.0%VVN461 0.5%Vehicle
Started303031
Completed303031
Not completed000

Outcome measures

PrimaryAnterior Chamber Cell (ACC): Categorical Cure

Proportion of subjects with grade of 0 using SUN Working Group Grading Scale (0 (none) to 4+ (\>50 cells in field). Note - higher values represent a WORSE outcome.

Time frame:
Day 14
Reported as:
Count of participants · Participants
Anterior Chamber Cell (ACC): Categorical Cure
ParticipantsVVN461 1.0%VVN461 0.5%Vehicle
Anterior Chamber Cell (ACC): Categorical Cure18166
SecondarySafety of VVN461

Number of subjects with Adverse Events

Time frame:
Day 21
Reported as:
Count of participants · Participants
Safety of VVN461
ParticipantsVVN461 1.0%VVN461 0.5%Vehicle
Safety of VVN461233

Adverse events

Collected over 21 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VVN461 1.0%0/30 (0%)0/30 (0%)0/30 (0%)
VVN461 0.5%0/30 (0%)0/30 (0%)0/30 (0%)
Vehicle0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VVN461 1.0%VVN461 0.5%VehicleTotal
<=18 years0000
Between 18 and 65 years99725
>=65 years21212466
Age, Continuous
Age, Continuous(years)VVN461 1.0%VVN461 0.5%VehicleTotal
Mean69.1 ± 7.2868.5 ± 8.5169.8 ± 7.9469.1 ± 6.79
Sex: Female, Male
Sex: Female, Male(Participants)VVN461 1.0%VVN461 0.5%VehicleTotal
Female14231855
Male1671336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VVN461 1.0%VVN461 0.5%VehicleTotal
American Indian or Alaska Native0000
Asian1225
Native Hawaiian or Other Pacific Islander0000
Black or African American43512
White23242269
More than one race1012
Unknown or Not Reported1113
Region of Enrollment
Region of Enrollment(participants)VVN461 1.0%VVN461 0.5%VehicleTotal
United States30303191
08

Study locations

10 sites
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • North Bay Eye Associates
    Petaluma, California 94954, United States
  • Martel Eye Associates
    Rancho Cordova, California 95670, United States
  • ICON Eye Care
    Grand Junction, Colorado 81501, United States
  • Levenson Eye Associates
    Jacksonville, Florida 32204, United States
  • Comprehensive Eye Care, Ltd
    Washington, Missouri 63090, United States
  • Center For Sight - Las Vegas
    Las Vegas, Nevada 89145, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Keystone Research
    Austin, Texas 78731, United States
  • Houston Eye Associates
    Houston, Texas 77708, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in May 2024, 4 months.

Results were first posted in Jun 2025, 1 year after primary completion.

Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 4 months is below that.

Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Jan 11, 2024
Primary completionActual
May 15, 2024
CompletionActual
May 15, 2024
Results first posted
Jun 10, 2025
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06164743
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Jan 11, 2024
Primary completion
May 15, 2024
Completion
May 15, 2024
Results posted
Jun 10, 2025
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VVN461

Start the discussion